✦ LIBER ✦

Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial

✍ Scribed by Claudia O. Zein; Lisa M. Yerian; Prema Gogate; Rocio Lopez; John P. Kirwan; Ariel E. Feldstein; Arthur J. McCullough

Book ID: 102242675
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 301 KB
Volume: 54
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.24544

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose ursodeoxycholic acid therapy f

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

✍ Ulrich F. H. Leuschner; Birgit Lindenthal; Günter Herrmann; Joachim C. Arnold; M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

Randomized controlled trial testing the

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

✍ Kittichai Promrat; David E. Kleiner; Heather M. Niemeier; Elizabeth Jackvony; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 1 views

Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH. Weight reduction is typically recommended, but efficacy data are lacking. We performed a randomized controlled trial to examine the e

Betaine for nonalcoholic fatty liver dis

Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Correction: Betaine for nonalcoholic fat

Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 2 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.

Orlistat for overweight subjects with no

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

✍ Stephen A. Harrison; Will Fecht; Elizabeth M. Brunt; Brent A. Neuschwander-Tetri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

A phase 2, randomized, double-blind, pla

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

✍ Vlad Ratziu; Muhammad Y. Sheikh; Arun J. Sanyal; Joseph K. Lim; Hari Conjeevaram 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS-9450 has a potential for altering the course of the liver disease. In this phase 2, double-blind study, 124 subjects with